Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomization, Double Blind, Multicenter Phase II Clinical Trial to Evaluate the Imatinib for Prophylaxis of CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03343600 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT03343600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03343600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomization, Double Blind, Multicenter Phase II Clinical Trial to Evaluate the Imatinib for Prophylaxis of CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 9, 2017
Completion date
August 31, 2019
Enrollment
5 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

patients who have received allo-hsct